Comparative Study of Paclitaxel Liposome and Paclitaxel in Neoadjunvant Chemotherapy for Locally Advanced Cervical Cancer

Objective To compare the efficacy and safety of paclitaxel liposome and paclitaxel in neoadjunvant chemotherapy for locally advanced cervical cancer.Methods 55 comparability patients with locally advanced cervical were divided into treatment group(n=35)and control group(n=20).The patients in the treatment group were treated with paclitaxel liposome combined with carboplatin 135 mg·(m2)-1 of paclitaxel liposome at the first day given intravenously lasting for at least 3 hours,300 mg·(m2)-1 of carboplatin at the second day given intravenously 3 weeks as a cycle.Those patients in the control were treated with paclitaxel combined with carboplatin(same usage as in the tested group).At the end of the treatment cycle,the therapeutic effects and toxicity in both group were evaluated.Results The total effective rate in the treated and control groups were 85.7% and 55.0%,respectively.The difference was statistically significant(P0.05).Pathologic examination showed that one case and five cases of lymph node metastasis in the treated and control group,respectively,with remarkablely significance(P0.05).Referring to hematologic toxicity,no significant difference between the two groups was found.While the incidence of non-hematologic toxicity like skin rash and peripheral neuritis was higher in the control group than that in the treatment group,the difference was statistically significant(P0.01 or P0.05).Conclusion It is concluded that paclitaxel liposome is more effective and has less adverse reactions such as rash and peripheral nerve toxicity than paclitaxel.The paclitaxel liposome is a new adjunvant chemotherapy for locally advanced cervical cancer,providing patients more chance of surgical opation and improve prognosis.